|
| Press Releases |
|
 |
|
| Monday, December 7, 2020 |
|
|
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. ("Sinovac LS", previously known as Sinovac Research and Development Co., Ltd.), which will be funded by internal resources of the Group and result in a 15.03% equity interest in Sinovac LS. more info >> |
|
| Monday, November 30, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, more info >> |
|
| Friday, August 28, 2020 |
|
|
Sino Biopharm Announces 2020 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period"). more info >> |
|
| Thursday, May 28, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 First Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period"). more info >> |
|
| Tuesday, May 26, 2020 |
|
|
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug more info >> |
|
| Tuesday, May 19, 2020 |
|
|
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab more info >> |
|
| Monday, March 30, 2020 |
|
|
Sino Biopharm Announces 2019 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). more info >> |
|
| Tuesday, January 21, 2020 |
|
|
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO |
| Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. more info >> |
|
| Tuesday, November 26, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period"). more info >> |
|
| Thursday, August 29, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Interim Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced today its unaudited interim results for the six months ended 30 June 2019 (the "review period").
more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Oct 31, 2025 0:45 JST
|
|
|
Sharp to Introduce AQUOS sense10 Smartphone
Oct 31, 2025 0:27 JST
|
|
|
Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Oct 31, 2025 0:07 JST
|
|
|
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile"
Oct 31, 2025 21:45 HKT/SGT
|
|
|
Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
Oct 31, 2025 19:56 HKT/SGT
|
|
|
Saudi Arabia Assumes Chairmanship of INTOSAI
Oct 31, 2025 19:45 HKT/SGT
|
|
|
T-RIZE Strategically Collaborates with Republic and Canton to Launch the First New Construction Real Estate Equity Tokenization Deal on Canton Network, phase one of a $200M plan
Oct 31, 2025 15:50 HKT/SGT
|
|
|
IPO Watch - High-Margin International Business Scales Up Rapidly: Unpacking Hithium Energy Storage's Global Expansion Ambition Behind its Push for a Hong Kong Listing 
Oct 31, 2025 15:20 HKT/SGT
|
|
|
CIMC Group Announces the First Three Quarter Results for 2025
Oct 31, 2025 14:16 HKT/SGT
|
|
|
Hong Kong delegation concludes mission in Riyadh
Oct 31, 2025 11:19 HKT/SGT
|
|
|
The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong
Oct 31, 2025 09:19 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units
Oct 31, 2025 09:09 HKT/SGT
|
|
|
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 9:30 JST
|
|
|
TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations
Oct 31, 2025 04:00 HKT/SGT
|
|
|
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
